Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Albumin-bound paclitaxel - Celgene Corporation

Drug Profile

Albumin-bound paclitaxel - Celgene Corporation

Alternative Names: ABI-007; ABRAXANE; Abraxane; ABRAXUS; Coraxane; Coroxane; Nab-Paclitaxel; Systemic nanoparticle albumin-bound paclitaxel

Latest Information Update: 25 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abraxis BioScience
  • Developer Abraxis BioScience; AstraZeneca; Australian and New Zealand Urogenital and Prostate Cancer Group; Big Ten Cancer Research Consortium; Biotoscana; Cambridge University Hospitals; Cancer Research UK; Celgene Corporation; Columbia University; Eli Lilly and Company; Emory University; Fondazione Sandro Pitigliani; Genentech; Institut fuer Frauengesundheit; M. D. Anderson Cancer Center; Mayo Clinic; Merck Sharp & Dohme; National Cancer Institute (USA); NCIC Clinical Trials Group; New York University School of Medicine; Oncosur; PrECOG; Southeastern Gynecologic Oncology; Taiho Pharmaceutical; University of California, Davis; University of Iowa; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase II Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Small cell lung cancer; Urogenital cancer
  • Phase I/II Multiple myeloma; Solid tumours
  • No development reported Bladder cancer; Ovarian cancer; Prostate cancer
  • Discontinued Coronary artery restenosis; Peripheral arterial disorders; Vascular restenosis

Most Recent Events

  • 21 Sep 2019 Launched for Breast cancer (Combination therapy) in Japan (IV)
  • 01 Aug 2019 Celgene completes a phase III trial for Non-small cell lung cancer (Maintenance therapy, Metastatic disease, Late stage disease) in United Kingdom, Germany, Spain, Italy(NCT02027428)
  • 15 Jul 2019 HonorHealth Research Institute in collaboration with Celgene initiates a phase II trial for Pancreatic cancer (Metastatic disease, First-line therapy, Combination therapy) in USA (NCT03915444)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top